Edition:
India

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

12.66HKD
12:38pm IST
Change (% chg)

HK$-0.22 (-1.71%)
Prev Close
HK$12.88
Open
HK$12.98
Day's High
HK$12.98
Day's Low
HK$12.62
Volume
2,211,144
Avg. Vol
5,989,112
52-wk High
HK$16.42
52-wk Low
HK$8.21

Latest Key Developments (Source: Significant Developments)

3SBIO Posts HY Net Profit Attributable RMB321.3 MLN
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - 3SBio Inc <1530.HK>::HY NET PROFIT ATTRIBUTABLE TO OWNERS OF PARENT DECREASED BY 37.5% TO APPROXIMATELY RMB321.3 MILLION.HY REVENUE RMB2,642.9 MILLION, UP 21.6%.  Full Article

3Sbio Says Clinical Trial Application Approved By National Medical Products Administration
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - 3SBio Inc <1530.HK>::CLINICAL TRIAL APPLICATION OF RECOMBINANT HUMANIZED ANTI-INTERLEUKIN-17A MONOCLONAL ANTIBODY INJECTION SOLUTION APPROVED BY NMPA.NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED GROUP'S APPLICATION ON 31 JULY 2019.  Full Article

3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA
Thursday, 22 Feb 2018 

Feb 22 (Reuters) - 3SBio Inc <1530.HK>::TPIAO INJECTION GRANTED APPROVAL FOR CLINICAL TRIALS FOR ADDITIONAL INDICATION BY CHINA FOOD AND DRUG ADMINISTRATION​.  Full Article

3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - 3Sbio Inc <1530.HK>::UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​.  Full Article

3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - 3Sbio Inc <1530.HK>::‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​.  Full Article

3SBio Inc says 601a approved by China FDA for clinical trials ​
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - 3SBio Inc <1530.HK>:Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​.  Full Article